Bioheart, Inc.
13794 NW 4th Street
Suite 212
Sunrise,
FL 33325
United States - Map
Phone: 954-835-1500
Fax: 954-845-9976
Web Site: http://www.bioheartinc.com
| Bioheart, Inc., a biotechnology company, focuses on discovering, developing, and commercializing autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate is MyoCell, a clinical therapy designed to populate regions of scar tissue in a patient’s heart with autologous muscle cells, or cells from the patient’s body for improving cardiac function in chronic heart failure patients. The company’s products under development include Bioheart Acute Cell Therapy, an autologous adipose cell treatment for the treatment of acute heart damage; TGI 1200 Adipose Tissue Processing System, an automated device for the rapid processing of patient derived fat tissue; and MyoCell SDF-1, an Autologous cell therapy for the treatment of severe chronic damage to the heart and cells modified to express angiogenic factors. Its products candidates also include MyoCath, a Disposable endoventricular catheter for the delivery of biologic solutions to the myocardium; BioPace for the treatment of chronic abnormal heart rhythm; AlloCell, an Allogenic cell-therapy treatment for severe chronic damage to the heart; and MyoCath II, a second generation disposable endoventricular catheter to provide multidirectional cell injection for the delivery of biologic solutions to the myocardium. Bioheart, Inc. was founded in 1999 and is headquartered in Sunrise, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Howard J. Leonhardt Ph.D.,
Co-Founder, Chairman, Chief Exec. Officer and Chief Technology Officer |
$
150.00K | N/A | Mr. William H. Kline , 62
Chief Financial Officer and Principal Accounting Officer |
$
130.00K | N/A | Mr. Scott R. Bromley , 46
VP of PR |
$
130.00K | N/A | Ms. Catherine Sulawske-Guck , 38
VP of Admin. & HR and Corp. Sec. |
N/A
| N/A | Mr. Robert Lashinski ,
Consultant and Member of Board of Advisors |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.83% Nasdaq 0.00%
Profile
